Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies
K Ai, B Liu, X Chen, C Huang, liping Yang… - Journal of Hematology & …, 2024 - Springer
Chimeric antigen receptor (CAR)-T cell therapy demonstrates substantial efficacy in various
hematological malignancies. However, its application in solid tumors is still limited. Clinical …
hematological malignancies. However, its application in solid tumors is still limited. Clinical …
Chimeric Antigen Receptor (CAR) T-Cell therapy for patients with lung cancer: Current perspectives
J Maher - OncoTargets and Therapy, 2023 - Taylor & Francis
Immunotherapy using chimeric antigen receptor (CAR)-engineered T-cells has achieved
unprecedented efficacy in selected hematological cancers. However, solid tumors such as …
unprecedented efficacy in selected hematological cancers. However, solid tumors such as …
CAR-T cell technologies that interact with the tumour microenvironment in solid tumours
CA Taylor, M Glover, J Maher - Expert Review of Clinical …, 2024 - Taylor & Francis
Introduction Chimeric antigen receptor (CAR) T-cells have emerged as a ground-breaking
therapy for the treatment of hematological malignancies due to their capacity for rapid tumor …
therapy for the treatment of hematological malignancies due to their capacity for rapid tumor …
[HTML][HTML] Engineered Cellular Therapies for the Treatment of Thoracic Cancers
SM Erickson, BM Manning, A Kumar, MR Patel - Cancers, 2024 - mdpi.com
Thoracic malignancies (lung cancers and malignant pleural mesothelioma) are prevalent
worldwide and are associated with high morbidity and mortality. Effective treatments are …
worldwide and are associated with high morbidity and mortality. Effective treatments are …